Q&A: Roche Diagnostics' Daniel O'Day on Roche's Plans for Illumina
February 07, 2012
Q&A: Roche Diagnostics' Daniel O'Day on Roche's Plans for Illumina
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- MLL Developing RainDance, MiSeq Gene Panel for Myeloid Malignancies
August 15, 2012 / Clinical Sequencing News - IRON-II Study Uses 454 Sequencing to Investigate New Markers for Hematological Malignancies
September 12, 2012 / Clinical Sequencing News - Q&A: Ralph Schlapbach on Maintaining a Variety of Platforms at the Functional Genomics Center Zurich
July 24, 2012 / In Sequence - Roche's Bid for Illumina Likely to Increase, Other Suitors May Emerge, Analysts Say
January 31, 2012 / In Sequence - People in the News: Dan Zabrowski, Thomas Schinecker, Charles Dadswell
April 24, 2013 / Clinical Sequencing News